Director, DMPK / April, 2022 — February, 2026

• Set and executed DMPK strategy across multiple oncology programs, integrating all in vitro and in vivo ADME, PK, and PK/PD activities to support discovery, NCE optimization, and IND enabling packages (SW-682, SW-3431). • Served as core DMPK project team representative on six high profile programs spanning early discovery to early development, influencing project strategy and data driven decision making. • Conducted PK and PK/PD modeling, enabling human PK predictions, efficacious dose projections, and early DDI risk assessments. • Partnered seamlessly with Chemistry, Discovery Biology, Toxicology, Translational Medicine, CMC, and Clinical Pharmacology to ensure aligned, cross functional advancement of portfolio programs towards clinical trials (NCT06251310, second asset pending). • Built and staffed a new DMPK laboratory, increasing throughput and accelerating high‑quality data delivery in a fast‑paced, matrixed environment.

Senior Director, Performance Testing & Bioanalytical | / January, 2016 — March, 2022

• Directed in vitro and in vivo DMPK studies for dermatology and topical drug programs (e.g., skin permeation, PK studies). • Led MedPharm’s in vitro bioequivalence program, including protocol development, FDA audit hosting, and responses to FDA questions/requests. • Managed >$3M annual budget across personnel, consumables, and capital equipment. • Led a team of 12 scientists, fostering a high-performance culture and improving analytical throughput. • Built analytical capabilities at a new U.S. site, implementing automation and high-efficiency LC-MS/MS workflows. • Optimized IVPT assay analysis pipelines, increasing throughput and reducing turnaround times.

Research Investigator, DMPK / January, 2014 — January, 2016

• Supported DMPK IND package for Ibrexafungerp (IND #107,521) • Managed a cross-functional team executing in vitro ADME assays and in vivo PK studies. • Developed fit-for-purpose LC-MS/MS methods supporting DMPK workflows. • Designed and interpreted microsomal stability, permeability, plasma stability, and protein binding studies.

Associate Lab Director, Bioanalytical Division / January, 2006 — January, 2014

• Developed GLP-compliant LC-MS/MS methods for small molecules and peptides across diverse biological matrices. • Built tissue homogenization workflows enabling high-throughput sample processing. • Served as project manager for multiple sponsors and contributed to business development through conference presentations.

Research Scientist / January, 2004 — January, 2006

• Contributed to metabolomics platform development, including sample prep, LC-MS method development, instrument troubleshooting, and data analysis. • Supported LC-MS/MS, GC-MS, and derivatization workflows; supervised an Assistant Scientist.

GC-MS Chemist / January, 1998 — January, 1999

• Performed EPA-method GC-MS analyses for volatile organic compounds; generated client data packages. • Supervised volatile organics section operations.

GC Chemist / January, 1995 — January, 1998

• Conducted GC analyses for pesticides, herbicides, and PCBs; maintained and repaired instrumentation. • Performed volatile organic GC-MS analyses and delivered client data packages.